Opportunity Information: Apply for PA 13 016
Apply for PA 13 016
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Prescription Drug Abuse (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Nov 5, 2012 and posted on Nov 2, 2012.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts County governments Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses State governments Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Prescription Drug Abuse (R21) opportunity (Funding Opportunity Number PA-13-016) is a National Institutes of Health (NIH) funding announcement from the National Institute on Drug Abuse (NIDA) focused on stimulating innovative, early-stage research on prescription drug abuse. Using the NIH R21 mechanism, it is intended to support exploratory and developmental studies that can open up new lines of inquiry, generate preliminary data, or test novel approaches related to how and why prescription medications are misused, what harms result, and what can be done to prevent and treat prescription drug abuse more effectively.
At its core, the announcement calls for research that examines factors contributing to prescription drug abuse, describes and quantifies adverse outcomes, and develops or improves prevention, service delivery, and treatment strategies. NIDA encourages a broad set of scientific approaches, explicitly spanning basic science, clinical research, epidemiology, and health services research. This means a proposal could range from mechanistic work that helps explain vulnerability and drug effects, to clinical studies of misuse patterns and comorbidities, to population-level surveillance and risk modeling, to pragmatic research on how health systems can identify and reduce problematic prescribing and misuse.
A major emphasis is on defining the scope and nature of prescription drug abuse in a detailed, realistic way. Applicants are encouraged to characterize the problem by specific classes of medications and by combinations of drug types that are commonly used together. The announcement highlights prescription drug classes with high abuse liability, including analgesics (notably pain medications), stimulants, sedative/hypnotics, and anxiolytics. In addition to identifying which drugs are most involved, projects are encouraged to examine the etiology of abuse and identify which populations are most affected. This includes analyses by age group, race/ethnicity, gender, and psychiatric symptomatology, reflecting an interest in both health equity and the clinical complexity that often accompanies misuse.
The opportunity also encourages studies that look across multiple levels of influence rather than focusing only on individual behavior. Proposed work may center on individual- and patient-level factors (such as mental health symptoms, pain status, prior substance use, or environmental stressors), prescriber-level factors (such as prescribing practices, risk assessment, monitoring behaviors, or clinical decision-making), and health system factors (such as access to care, care coordination, policy and workflow, or the effectiveness of screening and referral pathways). In practical terms, NIDA is signaling that prescription drug abuse is shaped by the interaction of patients, clinicians, and systems, and that meaningful solutions often require understanding those interactions.
Another specific theme is the relationship between the prescribed medication, the medical indication for which it was originally prescribed, and the environmental and individual factors that contribute to misuse. The announcement gives examples of indications like pain, sleep disorders, anxiety disorders, and obesity. This framing invites research that distinguishes between appropriate medical use, problematic use, and nonmedical use, and that explores how clinical conditions and treatment contexts can elevate or reduce risk. It also leaves room for studies that consider how treatment decisions, symptom trajectories, and social environments (family context, community factors, availability of drugs, and stress exposure) influence the transition from legitimate use to misuse or disorder.
From an administrative standpoint, this is a discretionary grant program under CFDA 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement. The funding listing provides an award ceiling of $200,000, consistent with the exploratory nature of R21 projects. The opportunity was posted on November 2, 2012, created on November 5, 2012, and had an original and current closing date of January 7, 2016, with an archive date of February 7, 2016, indicating that this specific announcement is no longer active but remains a useful reference point for the types of projects NIDA seeks to support in this area.
Eligibility is broad and includes many kinds of domestic and non-domestic organizations. Eligible applicants listed include state, county, city/township, special district, and certain housing authorities; public and state-controlled institutions of higher education as well as private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (including faith-based and community-based organizations); small businesses and other for-profit organizations (other than small businesses are also included); independent school districts; and Native American tribal governments and tribal organizations. The eligibility notes also explicitly include various minority-serving institutions (such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities), as well as U.S. territories or possessions and foreign organizations and foreign components as permitted under NIH policy. In short, NIDA structured this opportunity to encourage participation from a wide range of research and community settings, including international entities where appropriate.
The full announcement was made available through NIH at the link provided in the source (http://grants.nih.gov/grants/guide/pa-files/PA-13-016.html). For technical issues accessing the announcement or linking problems, the contact point listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs): Prescription Drug Abuse (R21) - PA-13-016
What is the Prescription Drug Abuse (R21) opportunity (PA-13-016)?
PA-13-016 is a National Institutes of Health (NIH) funding announcement from the National Institute on Drug Abuse (NIDA). It uses the NIH R21 mechanism to stimulate innovative, early-stage research on prescription drug abuse, including why it happens, what harms result, and how prevention and treatment can be improved.
What is the goal of this funding announcement?
The goal is to support exploratory and developmental studies that can open new lines of inquiry, generate preliminary data, or test novel approaches related to prescription medication misuse and prescription drug abuse.
What research topics does NIDA want to support under this R21?
The announcement calls for research that (1) examines factors contributing to prescription drug abuse, (2) describes and quantifies adverse outcomes, and (3) develops or improves prevention, service delivery, and treatment strategies.
What kinds of scientific approaches are encouraged?
NIDA explicitly encourages a broad range of approaches spanning basic science, clinical research, epidemiology, and health services research. Projects may focus on mechanisms of vulnerability and drug effects, clinical misuse patterns and comorbidities, population surveillance and risk modeling, or pragmatic studies of health system strategies to reduce problematic prescribing and misuse.
Which prescription drug classes are specifically highlighted as having high abuse liability?
The announcement highlights analgesics (notably pain medications), stimulants, sedative/hypnotics, and anxiolytics as prescription drug classes with high abuse liability.
Does the announcement encourage studies of combinations of drugs?
Yes. Applicants are encouraged to characterize prescription drug abuse by specific medication classes and by combinations of drug types that are commonly used together.
Is defining the scope and nature of prescription drug abuse a major emphasis?
Yes. A major emphasis is on defining the scope and nature of prescription drug abuse in a detailed and realistic way, including which drugs are involved, how misuse occurs, and what populations are most affected.
What populations or subgroups does the announcement encourage researchers to examine?
The opportunity encourages identifying which populations are most affected, including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology.
Does the opportunity focus only on individual behavior?
No. The announcement encourages studies that look across multiple levels of influence, including individual- and patient-level factors, prescriber-level factors, and health system factors.
What are examples of individual- or patient-level factors mentioned?
Examples include mental health symptoms, pain status, prior substance use, and environmental stressors.
What are examples of prescriber-level factors mentioned?
Examples include prescribing practices, risk assessment, monitoring behaviors, and clinical decision-making.
What are examples of health system factors mentioned?
Examples include access to care, care coordination, policy and workflow, and the effectiveness of screening and referral pathways.
How does the announcement frame the relationship between prescribing, medical indication, and misuse risk?
A specific theme is the relationship between the prescribed medication, the medical indication for which it was originally prescribed, and environmental and individual factors that contribute to misuse.
Which medical indications are explicitly mentioned as examples?
The announcement provides examples of indications including pain, sleep disorders, anxiety disorders, and obesity.
Does the announcement distinguish between medical use and nonmedical use?
Yes. The framing invites research that distinguishes between appropriate medical use, problematic use, and nonmedical use, and explores how clinical conditions and treatment contexts can elevate or reduce risk.
What environmental or contextual influences are mentioned?
Examples include family context, community factors, availability of drugs, and stress exposure.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R21 mechanism, which is intended for exploratory and developmental research.
What is the CFDA number for this program?
The funding listing identifies this as a discretionary grant program under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the award ceiling listed for this opportunity?
The funding listing provides an award ceiling of $200,000, consistent with the exploratory nature of R21 projects.
Is this funding opportunity still open?
No. The original and current closing date was January 7, 2016, and the archive date was February 7, 2016, indicating that this specific announcement is no longer active.
When was this opportunity posted and created?
It was posted on November 2, 2012, and created on November 5, 2012.
Who is eligible to apply?
Eligibility is broad and includes many kinds of domestic and non-domestic organizations, including various government entities, institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), faith-based and community-based organizations, small businesses, other for-profit organizations, independent school districts, and Native American tribal governments and tribal organizations.
Are minority-serving institutions explicitly included?
Yes. The eligibility notes explicitly include minority-serving institutions such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities.
Are U.S. territories and foreign organizations allowed to apply?
Yes. The eligibility notes include U.S. territories or possessions and foreign organizations and foreign components as permitted under NIH policy.
Where can applicants find the full NIH announcement for PA-13-016?
The full announcement is available through NIH at http://grants.nih.gov/grants/guide/pa-files/PA-13-016.html.
Who should be contacted for technical problems accessing the announcement link?
For technical issues accessing the announcement or linking problems, the listed contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: FY 2013 Request for Proposals from Indian Tribes and Intertribal Consortia for Nonpoint Source Management Grants Under Clean Water Act (CWA) Section 319
Previous opportunity: Prescription Drug Abuse (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 016
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) Apply for RFA CA 13 001 Funding Number: RFA CA 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) Apply for RFA CA 13 002 Funding Number: RFA CA 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Stage Development of Innovative Technologies for Biospecimen Science (R21) Apply for RFA CA 13 003 Funding Number: RFA CA 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) Apply for RFA CA 13 004 Funding Number: RFA CA 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Limited Competition Palliative Care Research Co Operative (PCRC) (U24) Apply for RFA NR 13 004 Funding Number: RFA NR 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) Apply for PAR 13 036 Funding Number: PAR 13 036 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01) Apply for RFA NS 13 007 Funding Number: RFA NS 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS and Cancer Specimen Resource (ACSR) (UM1) Apply for RFA CA 13 005 Funding Number: RFA CA 13 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 13 048 Funding Number: PAR 13 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 13 049 Funding Number: PAR 13 049 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R01) Apply for PA 13 058 Funding Number: PA 13 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pain in Aging (R21) Apply for PA 13 059 Funding Number: PA 13 059 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R03) Apply for PA 13 060 Funding Number: PA 13 060 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Administrative Supplements to NCI Funded Research Projects Funding to Advance Research on Cancers in Women (Admin Supp) Apply for PAR 13 067 Funding Number: PAR 13 067 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 13 068 Funding Number: PAR 13 068 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 13 054 Funding Number: PAR 13 054 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 13 056 Funding Number: PAR 13 056 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Behavioral Integrative Treatment Development Program (R34) Apply for PA 13 078 Funding Number: PA 13 078 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Behavioral Integrative Treatment Development Program (R01) Apply for PA 13 077 Funding Number: PA 13 077 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Integrative Treatment Development Program (R03) Apply for PA 13 079 Funding Number: PA 13 079 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.